Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
TIMOLIDE 10-25 is a fixed-dose combination tablet containing hydrochlorothiazide (a thiazide diuretic) and timolol maleate (a non-selective beta-blocker) approved in 1981. It is indicated for hypertension management, leveraging dual mechanisms to reduce blood pressure through sodium excretion and cardiac output reduction. This combination provides synergistic antihypertensive effect in patients requiring multi-drug therapy.
Mature combination product approaching loss of exclusivity with moderate competitive pressure (30% intensity), indicating transition from growth to defensive positioning and likely team consolidation.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on TIMOLIDE presents limited career growth opportunity given its LOE-approaching lifecycle and zero linked job openings. Roles available would focus on defensive brand management, generic conversion strategy, and maintaining market access rather than innovation or expansion.
Worked on TIMOLIDE 10-25 at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.